Anemia is a common feature of CKD associated with poor outcomes. The current
management of patients with anemia in CKD is controversial, with recent clinical trials …

Anaemia is a commonly diagnosed complication among patients suffering with chronic
kidney disease. If left untreated, it may affect patient quality of life. There are several causes …

Background Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and regulates iron metabolism. Additional data are needed …

Background We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the
treatment of chronic kidney disease-related anemia in patients new to dialysis. Methods …

Prolyl hydroxylase domain oxygen sensors are dioxygenases that regulate the activity of
hypoxia-inducible factor (HIF), which controls renal and hepatic erythropoietin production …

The purpose of this focused update is to update the “2013 ACCF/AHA Guideline for the
Management of Heart Failure” 9 (2013 HF guideline) in areas in which new evidence has …

Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and …

Abstract Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl
hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb …

Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl-hydroxylase
inhibitor that promotes erythropoiesis through increasing endogenous erythropoietin …

Results Of 332 participants screened, 271 participants were randomized (safety evaluation:
271 participants; efficacy evaluation: 267 intent-to-treat population). The mean hemoglobin …